Skip to main content
S&P 5007,746.79+0.31%DOW52,512.49+0.26%NASDAQ26,536.13+0.22%BTC$81,121.00+0.67%ETH$2,359.18+0.63%GOLD$4,053.40-0.52%OIL$102.67+2.77%
Smart Investors Daily
SID Premium
ON

NASDAQ · ONCY

Oncolytics Biotech Inc.

Healthcare · Biotechnology

$0.46

Down-$0.03 (-5.41%)

Updated Oct 28, 2026, 6:49 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
100.06M
P/E ratio
-3.94
Dividend yield
0.00%
52-week range
$0.44 – $1.32
Volume
859.33K
Avg. volume
891.91K

Price performance · ONCY

ONCY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 27, 2026

ONCY closed at $0.46 after 21 trading sessions, down 31.46% for the selected period.

Last close
$0.46
Period change
-31.46%
Period low
$0.46
Period high
$0.67
Daily close
View OHLC price history
ONCY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 27, 2026$0.4703$0.4998$0.4601$0.4623859.33K
Oct 26, 2026$0.51$0.52$0.47$0.4732711.69K
Oct 23, 2026$0.505$0.5077$0.49$0.5023376.01K
Oct 22, 2026$0.5041$0.515$0.50$0.5002406.92K
Oct 21, 2026$0.50$0.5204$0.4907$0.5114771.83K
Oct 20, 2026$0.51$0.5229$0.49$0.49861.2M
Oct 19, 2026$0.5105$0.55$0.4901$0.4963697.04K
Oct 16, 2026$0.55$0.55$0.4851$0.49811.34M
Oct 15, 2026$0.55$0.5875$0.5211$0.54761.3M
Oct 14, 2026$0.495$0.56$0.4422$0.53823.15M
Oct 13, 2026$0.489$0.5033$0.45$0.494.2M
Oct 12, 2026$0.5702$0.5895$0.4414$0.47333.32M
Oct 9, 2026$0.5463$0.5696$0.525$0.5571.46M
Oct 8, 2026$0.60$0.6053$0.5418$0.54441.12M
Oct 7, 2026$0.59$0.61$0.5845$0.5958669.46K
Oct 6, 2026$0.60$0.605$0.5757$0.598859.73K
Oct 5, 2026$0.6362$0.6362$0.58$0.59691.94M
Oct 2, 2026$0.6521$0.6521$0.6211$0.631611.81K
Oct 1, 2026$0.668$0.6763$0.63$0.6412693.11K
Sep 30, 2026$0.68$0.6832$0.65$0.6682867.17K
Sep 29, 2026$0.67$0.68$0.66$0.6745784.33K

Latest ONCY news

The latest Smart Investors Daily articles mentioning ONCY.

Stock researchCompany · Overview

ONCY research

Overview

Company profile and research snapshot.

Company profile

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ONCY recent ratings
DateFirmRatingTarget
Aug 12, 2025H.C. WAINWRIGHT & CO., LLCBuy—
Aug 11, 2025H.C. WAINWRIGHT & CO., LLCBuy—
Aug 8, 2025JONES TRADINGHold—
Aug 7, 2025JONES TRADINGHold—
Jul 9, 2025LEEDE JONES GABLEBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer

Study launched earlier this year is expected to confirm previous efficacy signal in 2L KRAS-mutant MSS colorectal cancer study that saw 17 months PFS vs. 6 months for the historical standard of careSAN DIEGO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the Company is presenting a trial-in-progress abstract and e-poster discussing the REO 033 study at the Eu

Yahoo · Oct 14, 2026

Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment

Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5 Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in the first half of 2027 The Company will use the clinical data to focus and guide its strategy to combine pelareorep with a checkpoint inhibitor in gastrointestinal and additional tumors SAN DIEGO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By